Meet Our Analysts

Ed Arce
Managing Director, Senior Healthcare Analyst

  • Ed Arce is a Managing Director of Equity Research specializing in the biopharmaceutical and specialty pharmaceutical sectors.
  • Mr. Arce’s focus is in investment opportunities among hepatology, renal, infectious disease, gastrointestinal, endocrine, metabolic and select rare disease companies.
  • Mr. Arce has been engaged in institutionally-focused healthcare research since 2005. Prior to HCW, Mr. Arce was a Senior Research Analyst at ROTH Capital Partners. Mr. Arce’s previous sell-side experience includes MLV & Co, Wedbush Securities, UBS Securities and First Albany Capital.
  • Mr. Arce holds a Master of Science in Finance (MSF) degree from Boston College, as well as an MBA and a B.S. in Civil Engineering, both from Florida International University (FIU). Mr. Arce is also a Board-licensed Professional Engineer (P.E.), and a Level III CFA candidate.

Debjit Chattopadhyay
Managing Director, Senior Healthcare Analyst

  • Debjit Chattopadhyay is a Managing Director focused on healthcare research at HCW specializing in the biotechnology with a core focus on gene therapy, immune-oncology, and rare diseases.
  • Dr. Chattopadhyay has been a Wall Street healthcare analyst, on sell-side, since 2006. Dr. Chattopadhyay’s previous sell-side experience includes Janney Montgomery Scott, Roth Capital Partners, and Boenning & Scattergood. Most recently, Dr. Chattopadhyay was the Managing Director and head of biotechnology at Janney Montgomery Scott.
  • Dr. Chattopadhyay received his Ph.D. from the University of Connecticut and has served as an oncology research fellow at Memorial Sloan Kettering Cancer Center and also holds a Masters of Business Administration (MBA) degree from Drexel University.

Yi Chen, Ph.D., CFA
Managing Director, Senior Healthcare Analyst

  • Dr. Yi Chen is a Managing Director of Equity Research with expertise in the biotechnology and pharmaceutical sectors.
  • Dr. Chen’s focus is on investment opportunities in the U.S. healthcare sector as well as emerging growth opportunities in the China healthcare sector. Prior to joining H.C. Wainwright, Dr. Chen held positions as an Associate Director in healthcare equity research at both Aegis Capital Corp. and Morgan Joseph TriArtisan, LLC. He also worked as a trading associate at Zhang Capital Management, a New York-based buy-side fund. Dr. Chen’s research career focused on protein signaling domains utilizing an RNA interference approach during while he was a research associate at the City University of New York. He has published articles in leading peer-reviewed journals, presented research at various scientific conferences, and has been an instructor in biology laboratory courses at Hunter College in New York City.
  • Dr. Chen obtained his Ph.D. in biochemistry from the City University of New York in February 2007, and B.S. in Biophysics from Fudan University in July 1999. He is a Chartered Financial Analyst (CFA) charter holder.

Amit Dayal
Managing Director, Senior Technology Analyst

      • Amit Dayal is a Managing Director at HCW where he is focused on research for small cap growth companies listed in the U.S. Prior to joining HCW, Mr. Dayal was advising and investing in early stage technology startups. Prior to that, Mr. Dayal was a Senior Research Analyst at Rodman & Renshaw for seven years  where he focused on covering small and mid cap companies in verticals including TMT (Technology Media Telecom), Clean Tech, Industrials and Consumer. Mr. Dayal’s research coverage has included companies in emerging markets. His research emphasis is on underfollowed and growth oriented companies. Before joining Rodman & Renshaw, Mr. Dayal founded and later sold his own web services company that was operational in India and Nepal.
      • Mr. Dayal holds an MBA from Babson College, an M.Com from University of Delhi and a B.Com (Hons) from University of Delhi.

Kevin Dede, CFA
Managing Director, Senior Technology Analyst

      • Mr. Dede is a Managing Director and Equity Research Analyst at H.C. Wainwright. He has over 20 years of experience preparing institutional focused research covering several industries including telecommunications food chain, heavy industry, retail, financial services, and almost all realms of technology.  Mr. Dede began his career at Prudential Securities in 1992, and has subsequently worked at other sell-side investment banks including Montgomery Securities, Merriman Curhan & Ford, and most recently, Auriga LLC. Mr. Dede has been cited as a technology expert by Barrons, Bloomberg television/radio, and FOX News among other financial reporting agencies.
      • Mr. Dede has an MBA and an Engineering Degree from the U.S. Merchant Marine Academy.

Andrew Fein
Managing Director, Senior Healthcare Analyst

      • Andrew Fein is a Managing Director focused on healthcare research at HCW. Mr. Fein has more than a dozen years of biotechnology equity research experience. Previously, Mr. Fein headed the healthcare research effort at Chardan Capital Markets. Prior to working at Chardan, Mr. Fein held Managing Director/Senior Biotechnology Analyst positions at Jefferies, Piper Jaffray and Collins Stewart from 2005 to 2010. Mr. Fein, began his career at J.P. Morgan H&Q and first gained recognition as a Senior Analyst at Leerink Swann. He has received honorable mention numerous times from the Institutional Investor All-America research poll
      • Andrew received his Bachelor of Arts degree from Yale University.

Heiko Ihle, CFA
Managing Director, Senior Metals & Mining Analyst

      • Heiko Ihle covers companies in the Metals & Mining industry.  Prior to joining H.C. Wainwright, Mr. Ihle spent 2.5 years at Euro Pacific Capital as a Senior Research Analyst, where he was also focused on the Mining industry. Before this, he spent over 6 years working on Equity Research with Gabelli & Company in Rye, NY with a focus on the Industrials and E&C industries. Prior to his time at Gabelli, he completed summer internships with Deutsche Bank on the foreign exchange trading desk in New York, NY and in fixed income sales in Frankfurt, Germany.
      • A native of Germany, Mr. Ihle received his Bachelor in Finance and Management from the University of Illinois at Chicago in 2004 and his MBA from the University of Miami in 2006. He has been a CFA Charterholder since 2010 and is currently a member of the CFA Institute and the Stamford CFA Society.

Oren G. Livnat, CFA
Managing Director

  • Oren Livnat is a Managing Director focused on specialty pharmaceuticals equity research at HCW with over a decade of experience in the space on both the sell-side and the buy-side.
  • Mr. Livnat was most recently a Senior Analyst covering specialty and generic pharma at Iguana Healthcare Partners, a dedicated healthcare long/short hedge fund.
  • Prior to that Mr. Livnat was a Senior Analyst at JMP Securities covering commercial and development-stage companies. Previously, Mr. Livnat covered Spec Pharma at Jefferies LLC for four years.
  • Mr. Livnat began his career as an Associate at Natixis Bleichroeder in 2006. Mr. Livnat received a B.A. in Economics from Wesleyan University, and is a CFA charterholder.

Joseph Pantginis, Ph.D.
Managing Director, Senior Healthcare Analyst

      • Dr. Joseph Pantginis, Ph.D., is a Managing Director focused on healthcare research at H.C. Wainwright & Co.
      • Dr. Pantginis has over 15 years of experience in healthcare equity research. Prior to joining H.C. Wainwright, Dr. Pantginis was most recently Senior Research Analyst and Head of Biotechnology Research at ROTH Capital Partners. Prior positions included senior positions at Merriman, Canaccord Adams, Commerce Capital Markets, JBHanauer and Ladenburg. Prior to his equity research career, Dr. Pantginis worked at Regeneron Pharmaceuticals, where he founded the Retroviral Core Facility.
      • Dr. Pantginis earned a Ph.D. and M.S. in molecular genetics from the Albert Einstein College of Medicine as well as an M.B.A. from Pace University.

Swayampakula Ramakanth, Ph.D.
Managing Director, Senior Healthcare Analyst

      • Dr. Swayampakula Ramakanth joined HCW in June, 2014 to focus on healthcare research.
      • Dr. Ramakanth’s expertise consists of companies in the oncology, infectious diseases, metabolic disorders and animal health sectors. Dr. Ramakanth has over 10 years of experience as a life sciences equity analyst and 7 years of biotechnology industry experience. He has covered biotechnology and large cap pharmaceutical sectors.
      • Prior to joining H.C. Wainwright in June 2014, Dr. Ramakanth was a Junior Analyst at Jefferies and Merrill Lynch covering large cap pharmaceuticals, and at First Albany and Rodman & Renshaw covering biotechnology companies. Dr. Ramakanth previously conducted bench research at Regeneron Pharmaceuticals, Inc. and directed a preclinical drug development group.
      • Dr. Ramakanth earned his doctorate in Pharmacology/ Toxicology by characterizing a novel gene for a drug metabolizing enzyme.  His expertise includes drug metabolism, molecular biology and pre-clinical drug development. Dr. Ramakanth has presented at various regional and international conferences and published in peer-reviewed journals.  Dr. Ramakanth has a Ph.D. in Pharmacology/Toxicology from the University of Utah, a MBA from Rutgers University, M.S. in Pharmaceutics from Auburn University, and B. Pharm (Hons.) from BITS, India.  He held a post-doctoral fellowship at the University of Texas MD Anderson Cancer Center.

Raghuram Selvaraju, Ph.D.
Managing Director, Senior Healthcare Analyst

        • Raghuram Selvaraju Ph.D., is a Managing Director focused on healthcare research at H.C. Wainwright & Co.
        • Dr. Selvaraju possesses over a decade's worth of experience in healthcare equity research, and has been ranked by StarMine for earnings accuracy as well as The Wall Street Journal's "Best On The Street" survey for his stock-picking performance. In addition, Dr. Selvaraju has appeared numerous times on Bloomberg, CNBC, Business News Network and BTV to comment on drug development trends, healthcare reform policy, and pharma and biotech M&A.
        • Prior to joining H.C. Wainwright, Dr. Selvaraju held senior research positions at MLV & Co., Aegis Capital, Hapoalim Securities USA and Rodman & Renshaw LLC.
        • Dr. Selvaraju earned a Ph.D. in molecular neuroscience and cellular immunology as well as an M.S. degree in molecular biology from the University of Geneva in Switzerland, and an M.B.A. from Cornell University.

Edward White
Managing Director

  • Ed White is a Managing Director focused on healthcare research at HCW specializing in the biotechnology and specialty pharmaceutical sectors.
  • Mr. White’s focus is in opportunities among oncology, immune-oncology, infectious disease,  and gastrointestinal companies.
  • Mr. White has been a Wall Street healthcare analyst, on both the buy-side and sell-side, since 1996. Mr. White’s previous sell-side experience includes Fahnestock & Company (now Oppenheimer), Gerard, Klauer, Mattison & Company (now BMO Capital Markets), Deutsche Bank Securities, and a couple of boutique firms. At Deutsche Bank, he worked on two Institutional Investor ranked analyst teams.
  • Most recently, Mr. White was a senior biotech analyst at FBR & Company. On the buy-side, Mr. White was the senior U.S. healthcare analyst for Mitsubishi UFJ Trust in Banking for 6 ½ years where he was a member of a team that managed a fund that at its peak over $16 billion, including $10 billion in U.S. equities.
  • Mr. White holds a Masters of Business Administration (MBA) degree from Rensselaer Polytechnic Institute, as well as a B.S. in Biology, from Manhattan College. Mr. White also attended the Mount Sinai School of Medicine for 2 ½ years. Mr. White was recently recognized as the top biotech analyst in the 2017 Thompson/Reuters Survey for earnings estimate accuracy.